{"id":"yellow-fever-vaccine-live","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the replication of the vaccine virus in the body, which triggers an immune response and the production of antibodies and immune cells that can recognize and fight the yellow fever virus. The immune response is then maintained through the production of memory cells that can quickly respond to future infections.","oneSentence":"The live yellow fever vaccine stimulates an immune response by introducing a weakened form of the yellow fever virus, allowing the body to develop immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:21.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of yellow fever"}]},"trialDetails":[{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT07222059","phase":"PHASE3","title":"Phase 3 Single Arm, Open Study on vYF in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-10-23","conditions":"Yellow Fever","enrollment":254},{"nctId":"NCT07002060","phase":"PHASE3","title":"Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Yellow Fever Immunization","enrollment":640},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT05421611","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2023-05-11","conditions":"Yellow Fever","enrollment":1824},{"nctId":"NCT03725618","phase":"PHASE4","title":"Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-11-01","conditions":"Yellow Fever","enrollment":1788},{"nctId":"NCT04083430","phase":"PHASE4","title":"Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Aarhus","startDate":"2019-10-08","conditions":"Healthy, Cytotoxicity, Yellow Fever Vaccination Reaction","enrollment":60},{"nctId":"NCT06815835","phase":"PHASE3","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Measles, Rubella, Yellow Fever","enrollment":1530},{"nctId":"NCT03920111","phase":"NA","title":"Flavivirus Cross-priming Potential of IMOJEV","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2021-04-16","conditions":"Japanese Encephalitis","enrollment":19},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT05447377","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants","status":"UNKNOWN","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-09-16","conditions":"Yellow Fever","enrollment":2216},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":"Infectious Disease, Yellow Fever, Japanese Encephalitis","enrollment":70},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01488890","phase":"PHASE2","title":"Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12-06","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":390},{"nctId":"NCT02699099","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-10","conditions":"Malaria, Malaria Vaccines","enrollment":699},{"nctId":"NCT03116802","phase":"PHASE2","title":"Yellow Fever Vaccine on Statin/ Non Statin Subjects","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2017-03-08","conditions":"Yellow Fever Vaccine, Yellow Fever","enrollment":37},{"nctId":"NCT03541694","phase":"","title":"Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-11","conditions":"Yellow Fever","enrollment":622},{"nctId":"NCT02710045","phase":"NA","title":"The Interaction Between Measles and DTP Vaccination","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2007-11","conditions":"Non-target Heterologous Effects of Vaccines, Vaccine Interactions","enrollment":302},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT00723489","phase":"PHASE1, PHASE2","title":"Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-08","conditions":"Atopic Dermatitis","enrollment":82},{"nctId":"NCT00254826","phase":"PHASE1","title":"Yellow Fever Virus Vaccine and Immune Globulin Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Viremia","enrollment":80},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CONTRAINDICATED PRODUCT ADMINISTERED"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG EFFECT DECREASED"},{"count":1,"reaction":"FAECES HARD"},{"count":1,"reaction":"FLATULENCE"},{"count":1,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":1,"reaction":"MICTURITION URGENCY"},{"count":1,"reaction":"POLLAKIURIA"},{"count":1,"reaction":"URINARY RETENTION"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["vYF vaccine","Stamaril vaccine","YF-VAX vaccine"],"phase":"phase_3","status":"active","brandName":"Yellow fever vaccine (live)","genericName":"Yellow fever vaccine (live)","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"The live yellow fever vaccine stimulates an immune response by introducing a weakened form of the yellow fever virus, allowing the body to develop immunity. Used for Prevention of yellow fever.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}